Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial
Authors' conclusion
About one-third of individuals on monotherapy or low-dose dual AHT who discontinued treatment maintained controlled BP after one year.
Study context
- Population
- Hypertensive patients in primary care on monotherapy or low-dose dual antihypertensive therapy (AHT), without self-reported CV risk factors (other than hypertension) or target organ damage, with controlled blood pressure (BP) by home blood pressure measurements (HBPM)203 analysed
- Participants
- 218 patients
- Comparison
- Discontinuation of AHT
- AHT discontinuationn = 218
- Primary endpoint
- Maintaining normotension (<135/85 mmHg) by HBPM
- Follow-up
- One year
Methodological detailsmulticentre, non-randomized
- Multicentre
- Non-randomized
Primary result
As reported in the abstract
Maintained normotension (home BP <135/85 mmHg) without AHT · 1 year
Maintained BP <135/85 mmHg for 1 year without AHT
73
36%
Required resumption of AHT during follow-up
130
64%
Further findings
Maintaining normal BP, by baseline systolic HBPM (subgroup)
- Systolic HBPM < 120 mmHg
- 60%
- Systolic HBPM ≥ 120 mmHg
- 23%
Predictors of BP at one year
- Baseline HBPM predicted BP at one year; office BP or white-coat hypertension did not
Safety
| Outcome | Values |
|---|---|
| Ischaemic stroke | AHT discontinuation 1 events |
- Ischaemic stroke: patient with systolic HBPM > 120 mmHg at baseline
Original publication
Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial. Eur J Prev Cardiol. Published 21 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →